STOCK TITAN

Acrivon Therapeutics CEO, EVP report stock sales

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

At Acrivon Therapeutics, Inc. (ACRV), President and CEO Peter Blume-Jensen and EVP - Business Operations Kristina Masson reported shares sold on November 17, 2026: 1,276 shares held directly by Blume-Jensen and 504 shares held indirectly by Masson, at a reported weighted-average price of $1.45 per share. A broker made the sales to satisfy mandatory tax withholding upon restricted stock unit vesting. Reported post-transaction holdings were 2,228,776 shares for Blume-Jensen and 385,355 shares for Masson. No Rule 10b5-1 plan is reported.

Insider Blume-Jensen Peter, Masson Kristina
Role President and CEO | EVP - Business Operations
Sold 1,780 shs ($3K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 1,276 $1.45 $2K
Sale Common Stock F1, F2, F4 504 $1.45 $730.80
Holdings After Transaction: Common Stock — 2,228,776 shares (Direct); Common Stock — 385,355 shares (Indirect, See Footnote)
Footnotes (4)
  1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
  2. F2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting persons. The proceeds of all such sales were allocated to the employees, including the reporting persons, on a pro rata basis.
  3. F3. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
  4. F4. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Shares sold by Peter Blume-Jensen 1,276 shares Held directly; November 17, 2026
Shares sold by Kristina Masson 504 shares Held indirectly; November 17, 2026
Reported weighted-average sale price $1.45 per share Broker sale on November 17, 2026
Peter Blume-Jensen post-transaction holdings 2,228,776 shares Direct holdings following the reported sale
Kristina Masson post-transaction holdings 385,355 shares Indirect holdings following the reported sale
Broker sale for employee tax withholding 4,070 shares Group of issuer employees, including the reporting persons; November 17, 2026
restricted stock units financial
"mandatory tax withholding requirement upon vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"reflects the weighted average price of 4,070 shares sold by a broker"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Acrivon Therapeutics (ACRV) executives sell?

1,276 directly held shares and 504 indirectly held shares were reported sold by Peter Blume-Jensen and Kristina Masson, respectively, on November 17, 2026, at a reported weighted-average price of $1.45 per share. No Rule 10b5-1 plan is reported.

Why were Acrivon Therapeutics (ACRV) shares sold on November 17, 2026?

The broker sale satisfied mandatory tax withholding upon restricted stock unit vesting. A broker sold 4,070 shares for a group of issuer employees, including the reporting persons, and allocated the proceeds to employees pro rata.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blume-Jensen Peter

(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026S(1)1,276D$1.45(2)2,228,776D(3)
Common Stock11/17/2026S(1)504D$1.45(2)385,355ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Blume-Jensen Peter

(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
Masson Kristina

(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
XOfficer (give title below)Other (specify below)
EVP - Business Operations
Explanation of Responses:
1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting persons. The proceeds of all such sales were allocated to the employees, including the reporting persons, on a pro rata basis.
3. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
4. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen11/19/2026
/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading